1345713-71-4

Basic information

• Product Name: PF-04554878
• Synonyms: PF-04554878;Defactinib (VS-6063, PF-04554878);PF-4554878
• CAS NO: 1345713-71-4
• Molecular Formula: C20H21F3N8O3S
• Molecular Weight: 510.4927496
• Mol File: 1345713-71-4.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: PF-04554878(CAS DataBase Reference)
• NIST Chemistry Reference: PF-04554878(1345713-71-4)
• EPA Substance Registry System: PF-04554878(1345713-71-4)

Safety Data

• Hazardous Substances Data: 1345713-71-4(Hazardous Substances Data)

Usage

Description

PF-04554878, also known as revacept, is a novel small molecule glycoprotein IIb/IIIa receptor antagonist. It is a pharmaceutical compound designed to inhibit the binding of fibrinogen to activated platelets, thus preventing platelet aggregation and the formation of blood clots. This makes it a potential candidate for antiplatelet therapy, particularly for the prevention of thrombotic events in patients with coronary artery disease and acute coronary syndrome.

Uses

Used in Cardiovascular Medicine:
PF-04554878 is used as an antiplatelet therapy for the prevention of thrombotic events in patients with coronary artery disease and acute coronary syndrome. It functions by inhibiting the binding of fibrinogen to activated platelets, which helps in reducing the risk of cardiovascular events in high-risk patients.
Clinical studies have demonstrated promising results regarding the efficacy and safety of PF-04554878, indicating its potential as a new therapeutic option for the management of thrombotic disorders. Further research is ongoing to fully assess its capabilities and establish its place in the treatment protocols for cardiovascular conditions.